Hematology (Dec 2024)
Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial
- Hans Salwender,
- Niels Weinhold,
- Axel Benner,
- Kaya Miah,
- Maximilian Merz,
- Mathias Haenel,
- Christian Jehn,
- Elias Mai,
- Ekaterina Menis,
- Igor Blau,
- Christof Scheid,
- Dirk Hose,
- Anja Seckinger,
- Steffen Luntz,
- Britta Besemer,
- Markus Munder,
- Peter Brossart,
- Bertram Glass,
- Hans-Walter Lindemann,
- Katja Weisel,
- Christine Hanoun,
- Paul Schnitzler,
- Sarah Klemm,
- Hartmut Goldschmidt,
- Marc Raab,
- Ahmet Elmaagacli
Affiliations
- Hans Salwender
- Department of Oncology and Hematology, Asklepios Hospital Hamburg Altona, Hamburg, Germany
- Niels Weinhold
- Department of Oncology and Hematology, Medizinische Klinik Heidelberg, Heidelberg, Germany
- Axel Benner
- Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany
- Kaya Miah
- Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany
- Maximilian Merz
- Department of Hematology and Cell Therapy, University Hospital Leipzig, Leipzig, Germany
- Mathias Haenel
- Department of Oncology and Hematology, Klinikum Chemnitz, Chemnitz, Germany
- Christian Jehn
- Department of Hematology/Oncology and Stem Cell Transplantation, AK St. Georg, Hamburg, Germany
- Elias Mai
- Department of Oncology and Hematology, Medizinische Klinik Heidelberg, Heidelberg, Germany
- Ekaterina Menis
- Department of Oncology and Hematology, Medizinische Klinik Heidelberg, Heidelberg, Germany
- Igor Blau
- Department of Oncology and Hematology, Charité Universitätsmedizin, Berlin, Germany
- Christof Scheid
- Department of Oncology and Hematology, University Hospital Cologne, Cologne, Germany
- Dirk Hose
- Laboratory of Hematology and Immunology & Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium
- Anja Seckinger
- Laboratory of Hematology and Immunology & Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium
- Steffen Luntz
- Department of Oncology and Hematology, Coordination Centre for Clinical Trials (KKS), Heidelberg, Germany
- Britta Besemer
- Department of Oncology and Hematology, University Hospital Tubingen, Tubingen, Germany
- Markus Munder
- Department of Oncology and Hematology, University Medical Center Mainz, Mainz, Germany
- Peter Brossart
- Department of Oncology and Hematology, University Hospital Bonn, Bonn, Germany
- Bertram Glass
- Department of Oncology and Hematology, Helios Hospital Berlin Buch, Buch, Germany
- Hans-Walter Lindemann
- Department of Oncology and Hematology, Kath. Krankenhaus Hagen, Hagen, Germany
- Katja Weisel
- Department of Oncology and Hematology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- Christine Hanoun
- Department of Oncology and Hematology, University Hospital Essen, Essen, Germany
- Paul Schnitzler
- Zentrum für Infektiologie, Virologie Universitätsklinikum Heidelberg, Heidelberg, Germany
- Sarah Klemm
- Zentrum für Infektiologie, Virologie Universitätsklinikum Heidelberg, Heidelberg, Germany
- Hartmut Goldschmidt
- Department of Oncology and Hematology, Medizinische Klinik Heidelberg, Heidelberg, Germany
- Marc Raab
- Department of Oncology and Hematology, Medizinische Klinik Heidelberg, Heidelberg, Germany
- Ahmet Elmaagacli
- Department of Hematology/Oncology and Stem Cell Transplantation, AK St. Georg, Hamburg, Germany
- DOI
- https://doi.org/10.1080/16078454.2024.2320006
- Journal volume & issue
-
Vol. 29,
no. 1
Abstract
ABSTRACTObjectives The seroprevalence of antibodies against Cytomegalovirus (CMV) is an established poor prognostic factor for patients receiving an allogeneic stem cell transplantation. However, the impact of CMV serology on outcome after autologous stem cell transplantation remains unknown.Methods Here, we analyzed the CMV immunoglobulin (Ig) serology of 446 newly-diagnosed multiple myeloma (MM) patients of the GMMG-MM5 phase III trial with a median follow-up of 58 months.Results CMV IgG and IgM positivity was seen in 51% and 6% of the patients, respectively. In multivariate analysis CMV IgG and CMV IgM serology show an age-depending effect for PFS. We identified positive CMV IgG/positive CMV IgM serology as an age-depending beneficial factor on PFS.Discussion Younger patients with a positive CMV IgG/positive CMV IgM serology experienced a favorable effect on PFS, whereas a positive CMV IgG/positive CMV IgM serology at older age has a disadvantageous effect on PFS.
Keywords
- CMV
- CMV IgM
- multiple myeloma
- GMMG-MM5 Phase III Trial
- autologous stem cell transplantation
- maintenance therapy
